Scancell to Present at 2024 AACR Annual Meeting
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your SCLP notes
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, today announces that Professor Lindy Durrant will be presenting at American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California on 5-10 April 2024.
Scancell will present data on its open-label Phase 2 SCOPE trial, investigating its cancer vaccine, SCIB1, in combination with checkpoint inhibitors (CPIs) in advanced melanoma. SCIB1 previously demonstrated an 85% response rate among 13 first-line advanced melanoma patients.
The AACR conference is an internationally recognized annual meeting, serving as a focal point of the cancer research community where the latest advances in the cancer space can be shared amongst world leading experts. Scancell is presenting as part of the 'Cancer Vaccines: Ready for Prime Time?' clinical trials symposium, covering progress from a number of innovative clinical stage cancer vaccines, including follow up data from the BioNTech mRNA vaccine.
Presentation Details:
Title: A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label Phase 2 SCOPE Trial
Session: CTMS01 - Cancer Vaccines: Ready for Prime Time?
Session Date and Time: Sunday 7 April 2024, 3:50 PM - 4:00 PM PST
Location: Ballroom 20 AB - Upper Level - Convention Center
Published Abstract Number: CT024
Speaker: Professor Lindy Durrant, Chief Executive Officer and Chief Scientific Officer
Authors: H. Shaw, P. Patel, M. Payne, S. Kumar, M. Highley, K. Prasad, R. Board, C. Barlow, S. Danson, R. Miller, G. Goodhew, F. Master, L. Durrant
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.